We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

152 hedge funds and large institutions have $1.24B invested in Achillion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more call options, than puts

Call options by funds: $41.9M | Put options by funds: $17.2M

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

50% more capital invested

Capital invested by funds: $829M → $1.24B (+$415M)

8% more funds holding

Funds holding: 141152 (+11)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

4% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 49

Holders
152
Holders Change
+11
Holders Change %
+7.8%
% of All Funds
3.99%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
31
Increased
47
Reduced
49
Closed
18
Calls
$41.9M
Puts
$17.2M
Net Calls
+$24.7M
Net Calls Change
+$10.4M
Name Holding Trade Value Shares
Change
Change in
Stake
MLICM
76
Metropolitan Life Insurance Company (MetLife)
New York
$898K
CLOS
77
Compagnie Lombard Odier SCmA
Switzerland
$866K +$63.6K +7,000 +10%
State Board of Administration of Florida Retirement System
78
State Board of Administration of Florida Retirement System
Florida
$812K
Barclays
79
Barclays
United Kingdom
$774K -$358K -39,352 -34%
Squarepoint
80
Squarepoint
New York
$764K +$644K +70,800 New
SFP
81
Santa Fe Partners
New Mexico
$751K -$63.3K -6,958 -9%
DekaBank Deutsche Girozentrale
82
DekaBank Deutsche Girozentrale
Germany
$749K +$9.09K +1,000 +1%
AIG
83
American International Group
New York
$747K +$2.56K +281 +0.4%
UBS AM
84
UBS AM
Illinois
$712K -$5.27M -580,200 -90%
CS
85
Credit Suisse
Switzerland
$637K -$487K -53,592 -48%
Creative Planning
86
Creative Planning
Kansas
$623K +$186K +20,500 +55%
Two Sigma Advisers
87
Two Sigma Advisers
New York
$615K +$518K +57,000 New
Royal Bank of Canada
88
Royal Bank of Canada
Ontario, Canada
$568K +$419K +46,063 +697%
CA
89
Commerzbank Aktiengesellschaft
Germany
$549K +$13.5K +1,484 +3%
VOYA Investment Management
90
VOYA Investment Management
Georgia
$530K
PPA
91
Parametric Portfolio Associates
Washington
$508K +$32.1K +3,535 +8%
DC
92
Deere & Company
Illinois
$461K +$388K +42,709 New
Allianz Asset Management
93
Allianz Asset Management
Germany
$457K +$385K +42,400 New
Cambridge Investment Research Advisors
94
Cambridge Investment Research Advisors
Iowa
$451K +$182K +19,975 +92%
William Blair & Company
95
William Blair & Company
Illinois
$435K -$324K -35,600 -47%
NSEDCP
96
NJ State Employees Deferred Compensation Plan
New Jersey
$432K
QIM
97
Quantitative Investment Management
Virginia
$430K +$175K +19,200 +93%
Two Sigma Investments
98
Two Sigma Investments
New York
$405K +$341K +37,500 New
Norges Bank
99
Norges Bank
Norway
$372K
WPP
100
Whalerock Point Partners
Rhode Island
$367K -$27.3K -3,000 -8%

ACHN Hedge Fund Activity: Q4 2015 in Review

152 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2015, worth a combined $1.24B — up 50% from $829M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ACHN positions and 18 closed out — a net gain of 13 holders — while 47 added to existing stakes and 49 trimmed.

The largest buyer was Millennium Management, adding an estimated $41.3M. The largest seller was Wellington Management Group, cutting an estimated $69.5M.

  • 152 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2015, up from 141 in Q3 2015.
  • Funds reported $1.24B of Achillion Pharmaceuticals stock for Q4 2015, up 50% quarter-over-quarter.
  • 31 funds opened new Achillion Pharmaceuticals positions in Q4 2015 and 18 closed out, a net change of +13 holders.
  • The largest Achillion Pharmaceuticals buyer in Q4 2015 was Millennium Management, an estimated $41.3M added.
  • The largest Achillion Pharmaceuticals seller in Q4 2015 was Wellington Management Group, an estimated $69.5M sold.

Based on aggregated 13F filings for Q4 2015.